

AMENDMENTS TO THE CLAIMS

Please amend claims 1 and 18 as follows:

1. (previously amended) A process for long term in vivo transgene expression of a transgene from a delivered expression vector, comprising:
  - a) ~~delivering making~~ a non-viral, linear nucleic acid DNA vector comprising a nucleic acid sequence DNA expression cassette encoding the transgene, and;
  - b) delivering the non-viral, linear DNA vector to a cell, in vivo in a mammal; and,  
wherein expression of the transgene persists for an extended period of time  
expressing the transgene for longer than 7 days at levels 20% higher than the  
nucleic acid sequence present in a circular or supercoiled nucleic acid.
2. (original) The process of claim 1, wherein the nucleic acid contains blunt ends.
3. (original) The process of claim 1, wherein the nucleic acid contains sticky ends.
4. (original) The process of claim 1, wherein the nucleic acid contains a blunt end and a sticky end.
5. (original) The process of claim 1, wherein the linear nucleic acid is generated by restriction enzyme digestion.
6. (original) The process of claim 1, wherein the linear nucleic acid is generated by polymerase chain reaction.
7. (original) The process of claim 1, wherein the nucleic acid contains an expression cassette isolated from a plasmid backbone.
8. (previously amended) The process of claim 1, wherein the nucleic acid contains an expression cassette which is flanked by sequence derived from inner Tn5 transposase recognition elements.
9. (original) The process of claim 8, wherein the nucleic acid ends are blunt.
10. (previously amended) The process of claim 1, wherein the nucleic acid contains an expression cassette which is flanked by sequence derived from inner Tn5 transposase recognition elements.
11. (original) The process of claim 10, wherein the nucleic acid ends are blunt.

12. (previously amended) The process of claim 1, wherein the nucleic acid contains an expression cassette which is flanked by chimeric ends derived from Tn5 transposase recognition elements.
13. (original) The process of claim 12, wherein the nucleic acid ends are blunt.
14. (original) The process of claim 1, wherein the nucleic acid is delivered to cells intravascularly.
15. (original) The process of claim 1, wherein the nucleic acid are delivered intravascularly using pressure.
16. (original) The process of claim 1, wherein the nucleic acid is delivered by direct intramuscular injection.
17. (original) The process of claim 1, wherein the nucleic acid is delivered by direct interstitial injection.
18. (previously amended) A process for long term *in vivo* expression of a transgene expression from a delivered expression vector, comprising:
  - a) generating a non-viral, linear nucleic acid DNA vector comprising an DNA expression cassettes to express the transgene,
  - b) delivering the linear nucleic acid DNA vector to a mammalian cell; and,
  - c) expressing the transgene for an extended period of time longer than 7 days at levels 20% higher than the expression cassette present in a circular or supercoiled nucleic acid.
19. (original) The process of claim 18, wherein the linear nucleic acid vector is prepared by restriction enzyme digestion.
20. (original) The process of claim 18, wherein the linear nucleic acid vector is prepared by polymerase chain reaction.